QuidelOrtho Q3 2026 Earnings Conference Call - ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC

Explicit Guidance:

• Full-year 2026 total revenue guidance narrowed to $2.50 billion – $2.52 billion (previously $2.52 billion – $2.60 billion), primarily due to updated China destocking and pricing expectations.
• Full-year 2026 Adjusted EBITDA guidance of $540 million – $545 million.
• Full-year 2026 Adjusted EPS guidance of $0.65 – $0.70.
• China revenue expected to represent approximately 8% of total company revenue in 2026, declining to 4% – 5% in 2027.
• Labs and Immunohematology (ex-China) expected to deliver low-to-mid-single-digit organic growth in 2026.
• Respiratory season outlook for Q4 2026 incorporates cautious assumptions based on Q3 trends, anticipating continued lower activity compared to prior year.
• Fourth quarter 2026 Free Cash Flow expected to be negatively impacted by cash outflows associated with one-time restructuring charges.

Business-Segment Outlook:

• Core Diagnostics: Labs revenue ex-China grew 4% and Immunohematology grew 3% in Q3 2026, reflecting steady demand; Vitros 450 analyzer launch expanding to additional international markets in 2026-2027 to serve low-volume labs.
• Point-of-Care (POC): Revenue declined 27% YoY in Q3 2026, driven by a 39% drop in respiratory tests; SOFIA, TRIAGE, and NULEXA product lines will be grouped into a new POC diagnostics business unit.
• Respiratory Strategy: Focus shifting to building placements, driving utilization, and expanding installed base ahead of the 2027-2028 respiratory season; NULEXA platform expected to expand beyond initial respiratory menu with scalable molecular capabilities.
• China Operations: Expect continued customer destocking and reduced inventory through the remainder of 2026; pricing pressure and competitive volume impacts anticipated to materialize fully in 2027 as provincial implementation of nationwide IVD guidelines rolls out in 2027.

Market and Competitive Outlook:

• China Market Structure: Nationwide IVD pricing guidelines finalized; provincial implementation expected to begin in six provinces by end of 2026, with full pricing impact and competitive pressure expected in 2027.
• Competitive Positioning: Share in respiratory testing remains stable despite volume declines; underlying fundamentals in Labs and Immunohematology described as resilient with high win and renewal rates ex-China.
• Product Mix: Adjusted gross margin in Q3 2026 included ~300 bps of non-recurring benefits from tariff refunds and vendor credits; margin outlook for Q4 assumes exclusion of these one-time benefits.

Macro / Industry Outlook:

• Economic Headwinds: Respiratory testing demand remains softer than prior year; China destocking driven by regulatory pricing changes creates a significant near-term macro drag.
• Regulatory Environment: Implementation of China's IVD pricing guidelines introduces uncertainty regarding provincial timing and permanent pricing differentials; management views current pricing impact as a structural change necessitating business model evolution.
• Currency: All year-over-year revenue growth rates provided on a constant currency basis.

Strategic Initiatives:

• Cost Transformation Program: New enterprise restructuring program expected to deliver over $80 million in annual savings starting in 2027, with savings ramping through the year (weighted to second half).
• Operating Model Restructure: Transition from region-based to business unit-led model (Core Diagnostics and Point-of-Care Diagnostics) to increase customer focus and accountability; one-time restructuring charges of $30 million – $35 million expected in Q4 2026.
• Capacity & Investment: New Lexa (NULEXA) manufacturing and commercial launch capabilities established post-acquisition; capital expenditures managed with increased discipline, net capex at $19 million in Q3 2026 vs $49 million prior year.
• Financial Priorities: Focus on improving profitability, increasing free cash flow, and reducing net leverage (currently 4.5x, with credit agreement amended to allow up to 5.5x leverage through Q2 2028).

Risks and Headwinds to Outlook:

• China Uncertainty: Provincial implementation timelines for IVD guidelines remain uncertain; potential for deeper destocking and pricing pressure than currently modeled.
• Respiratory Variability: Inherent variability in respiratory trends and severity; early season activity does not guarantee higher peak volume or duration.
• Restructuring Execution: Risk of execution delays in cost transformation or failure to realize projected $80M savings; cash outflow timing for restructuring charges concentrated in Q4 2026.
• Working Capital: Continued pressure on working capital from China inventory reductions and softer respiratory demand impacting Q4 free cash flow.
• Market Share: Competitive pressures in China expected to impact volume in 2027; no guarantee of immediate return to prior growth trajectories in affected regions.

Management Tone on the Future:

• Confidence Level: High confidence in underlying business fundamentals (Labs/Immunohematology) outside China; cautious but disciplined tone regarding China headwinds and respiratory outlook.
• Strategic Commitment: Management emphasizes "decisive" action and "structural" improvement, framing restructuring not as a temporary fix but as a necessary evolution for long-term profitability.
• Forward Outlook: Optimistic on the ability of the new operating model and cost savings to "more than offset" near-term China headwinds in 2027; focus on deleveraging and cash generation as primary near-term metrics.

Miscellaneous:

• Acquisition Status: NULEXA acquisition integration progressing; no specific comment on potential divestiture of NULEXA or China assets, though management states all options are being reviewed to optimize shareholder value.
• Guidance Assumptions: Guidance incorporates cautious Q4 respiratory assumptions based on Q3 data; no new specific product launch dates provided beyond the ongoing global expansion of Vitros 450.